MX343540B - Compuesto de tiazol y metodo de preparacion y uso del mismo. - Google Patents
Compuesto de tiazol y metodo de preparacion y uso del mismo.Info
- Publication number
- MX343540B MX343540B MX2013013048A MX2013013048A MX343540B MX 343540 B MX343540 B MX 343540B MX 2013013048 A MX2013013048 A MX 2013013048A MX 2013013048 A MX2013013048 A MX 2013013048A MX 343540 B MX343540 B MX 343540B
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- thiazole compound
- invention disclosed
- present
- antitumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/58—Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente invención describe una clase de compuestos de tiazol de la fórmula general (I) (ver Fórmula) el método de preparación y uso de los mismos. Más particularmente, la presente invención describe un derivado de largazol de producto natural, el método de preparación del mismo y el uso en el campo de tratamiento de antitumor y esclerosis múltiple como un inhibidor de histona desacetilasa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110120207.9A CN102775368B (zh) | 2011-05-10 | 2011-05-10 | 一类噻唑类化合物及其制备方法和用途 |
PCT/CN2012/075142 WO2012152208A1 (zh) | 2011-05-10 | 2012-05-07 | 一类噻唑类化合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013013048A MX2013013048A (es) | 2014-09-25 |
MX343540B true MX343540B (es) | 2016-11-08 |
Family
ID=47120501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013013048A MX343540B (es) | 2011-05-10 | 2012-05-07 | Compuesto de tiazol y metodo de preparacion y uso del mismo. |
Country Status (10)
Country | Link |
---|---|
US (1) | US9216962B2 (es) |
EP (1) | EP2708534B1 (es) |
JP (1) | JP6236382B2 (es) |
KR (1) | KR101577520B1 (es) |
CN (1) | CN102775368B (es) |
AU (1) | AU2012253019B2 (es) |
BR (1) | BR112013028894B1 (es) |
CA (1) | CA2835705C (es) |
MX (1) | MX343540B (es) |
WO (1) | WO2012152208A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2903081A1 (en) * | 2013-03-14 | 2014-09-25 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
CN104974108B (zh) * | 2014-04-04 | 2017-11-17 | 中国科学院上海药物研究所 | 一类2,2’‑串联双噻唑类化合物及其制备方法和用途 |
JP6600319B2 (ja) * | 2014-06-02 | 2019-10-30 | シーエイチディーアイ ファウンデーション,インコーポレーテッド | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 |
CN105315226A (zh) * | 2014-07-11 | 2016-02-10 | 中国科学院生态环境研究中心 | 一种以羧酸为底物一锅法合成2,4-二取代噻唑的新方法 |
DK3297992T3 (da) | 2015-05-22 | 2020-04-20 | Chong Kun Dang Pharmaceutical Corp | Heterocykliske alkylderivatforbindelser som selektive histondeacetylase-inhibitorer og farmaceutiske sammensætninger omfattende samme |
CN107793375A (zh) | 2016-08-31 | 2018-03-13 | 中国科学院上海药物研究所 | 一类芳基2,2’‑串联双噻唑类化合物及其制备方法和用途 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1378450A (zh) * | 1999-09-08 | 2002-11-06 | 斯隆-凯特林癌症研究院 | 新型细胞分化剂和组蛋白脱乙酰基酶抑制剂及其使用方法 |
CA2423868C (en) * | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
EP2269609A3 (en) * | 2001-10-16 | 2012-07-11 | Sloan-Kettering Institute for Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain with SAHA |
WO2003070691A1 (fr) * | 2002-02-21 | 2003-08-28 | Osaka Industrial Promotion Organization | Derive de n-hydroxycarboxamide |
ZA200507751B (en) * | 2003-04-07 | 2007-01-31 | Axys Pharm Inc | Novel hydroxamates as therapeutic agents |
US7842835B2 (en) * | 2003-07-07 | 2010-11-30 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
WO2005007091A2 (en) * | 2003-07-07 | 2005-01-27 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
WO2005019174A1 (en) * | 2003-08-20 | 2005-03-03 | Axys Pharmaceuticals, Inc. | Acetylene derivatives as inhibitors of histone deacetylase |
TW200524575A (en) * | 2003-10-27 | 2005-08-01 | S Bio Pte Ltd | Biaryl linked hydroxamates: preparation and pharmaceutical applications |
JP4946861B2 (ja) * | 2004-08-09 | 2012-06-06 | アステラス製薬株式会社 | ヒストンデアセチラーゼ(hdac)の阻害活性を有するヒドロキシアミド化合物 |
JP2008510821A (ja) * | 2004-08-25 | 2008-04-10 | メルク エンド カムパニー インコーポレーテッド | ヒストンデアセチラーゼ阻害剤 |
AR050552A1 (es) * | 2004-09-02 | 2006-11-01 | Osi Pharm Inc | Mercaptoamidas como inhibidores de histona desacetilasa |
ITFI20050041A1 (it) * | 2005-03-15 | 2006-09-16 | Menarini Internat Operations Luxembourg Sa | Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono |
CN1834095B (zh) * | 2005-03-18 | 2011-04-20 | 中国科学院上海药物研究所 | 一类非核苷类抗病毒抑制剂及其制备方法和用途 |
CA2603986A1 (en) * | 2005-04-20 | 2006-11-02 | Merck & Co., Inc. | Benzothiophene hydroxamic acid derivatives |
AU2007282080B2 (en) * | 2006-08-03 | 2013-06-27 | Georgetown University | Isoform-selective HDAC inhibitors |
US8030344B2 (en) * | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
WO2009055917A1 (en) * | 2007-11-02 | 2009-05-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
EP2330894B8 (en) * | 2008-09-03 | 2017-04-19 | BioMarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
-
2011
- 2011-05-10 CN CN201110120207.9A patent/CN102775368B/zh active Active
-
2012
- 2012-05-07 KR KR1020137031882A patent/KR101577520B1/ko active IP Right Grant
- 2012-05-07 CA CA2835705A patent/CA2835705C/en active Active
- 2012-05-07 US US14/116,944 patent/US9216962B2/en active Active
- 2012-05-07 BR BR112013028894-9A patent/BR112013028894B1/pt active IP Right Grant
- 2012-05-07 AU AU2012253019A patent/AU2012253019B2/en active Active
- 2012-05-07 WO PCT/CN2012/075142 patent/WO2012152208A1/zh active Application Filing
- 2012-05-07 MX MX2013013048A patent/MX343540B/es active IP Right Grant
- 2012-05-07 JP JP2014509592A patent/JP6236382B2/ja active Active
- 2012-05-07 EP EP12781747.6A patent/EP2708534B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2013013048A (es) | 2014-09-25 |
EP2708534A4 (en) | 2015-02-18 |
CN102775368B (zh) | 2016-08-17 |
AU2012253019B2 (en) | 2016-03-03 |
WO2012152208A1 (zh) | 2012-11-15 |
CA2835705A1 (en) | 2012-11-15 |
CA2835705C (en) | 2016-01-19 |
EP2708534B1 (en) | 2017-07-12 |
JP2014517831A (ja) | 2014-07-24 |
US20140148600A1 (en) | 2014-05-29 |
AU2012253019A1 (en) | 2013-11-28 |
US9216962B2 (en) | 2015-12-22 |
NZ617505A (en) | 2015-11-27 |
EP2708534A1 (en) | 2014-03-19 |
BR112013028894A2 (pt) | 2016-09-06 |
BR112013028894B1 (pt) | 2021-06-29 |
KR20140028046A (ko) | 2014-03-07 |
JP6236382B2 (ja) | 2017-11-22 |
KR101577520B1 (ko) | 2015-12-14 |
CN102775368A (zh) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012214029A8 (en) | Rorgammat inhibitors | |
GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
MY163394A (en) | Substituted aminobutyric derivates as neprilysin inhibitors | |
AU2012324803A8 (en) | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | |
PH12015501150B1 (en) | Compounds and their methods of use | |
MY165087A (en) | Neprilysin inhibitors | |
WO2012135113A3 (en) | Cyclopropylamines as lsd1 inhibitors | |
UA111382C2 (uk) | Інгібітори протеїнкінази | |
IN2014MN01183A (es) | ||
IN2014CN04676A (es) | ||
AU2012321815A8 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
WO2011153157A3 (en) | Benzoquinolone inhibitors of vmat2 | |
MX2016002794A (es) | Compuestos antiproliferativos. | |
TN2014000095A1 (en) | Pharmaceutical compositions | |
MX2013006802A (es) | Inhibidores de neprilisina. | |
CY1121825T1 (el) | Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου | |
UA111744C2 (uk) | ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk | |
IN2014DN10670A (es) | ||
TN2015000574A1 (en) | Compounds and compositions as inhibitors of mek | |
MX343540B (es) | Compuesto de tiazol y metodo de preparacion y uso del mismo. | |
TN2013000239A1 (en) | New form of administration of enkephalinase inhibitor | |
CA2887539C (en) | Azaquinazoline carboxamide derivatives | |
UA115583C2 (uk) | Азетидинілоксифенілпіролідинові сполуки | |
WO2012154879A3 (en) | Autophagy inhibitors | |
MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |